<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">problendo</journal-id><journal-title-group><journal-title xml:lang="ru">Проблемы Эндокринологии</journal-title><trans-title-group xml:lang="en"><trans-title>Problems of Endocrinology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0375-9660</issn><issn pub-type="epub">2308-1430</issn><publisher><publisher-name>Endocrinology Research Centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/probl9567</article-id><article-id custom-type="elpub" pub-id-type="custom">problendo-9567</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Original Studies</subject></subj-group></article-categories><title-group><article-title>Иммунорегуляторные белки и цитокины в крови пациентов с болезнью Грейвса</article-title><trans-title-group xml:lang="en"><trans-title>Immunoregulatory proteins and cytokines in the blood of patients with Graves’ disease</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8790-9337</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Маклакова</surname><given-names>Татьяна Петровна</given-names></name><name name-style="western" xml:lang="en"><surname>Maklakova</surname><given-names>Tatjana P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><bio xml:lang="en"><p>PhD, MD, Professor</p></bio><email xlink:type="simple">maclacovatat@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9183-7663</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зорина</surname><given-names>Вероника Николаевна</given-names></name><name name-style="western" xml:lang="en"><surname>Zorina</surname><given-names>Veronika N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.б.н.</p></bio><bio xml:lang="en"><p>PhD, MD</p></bio><email xlink:type="simple">nilimmun@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6982-9058</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Янышева</surname><given-names>Анна Владимировна</given-names></name><name name-style="western" xml:lang="en"><surname>Yanysheva</surname><given-names>Anna V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>врач эндокринолог, клинический ординатор кафедры эндокринологии и диабетологии</p><p> </p></bio><bio xml:lang="en"><p>endocrinologist, clinical resident of the Department of Endocrinology and Diabetology</p></bio><email xlink:type="simple">Anna-nik_06@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5770-1348</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мезенцева</surname><given-names>Екатерина Вадимовна</given-names></name><name name-style="western" xml:lang="en"><surname>Mezentseva</surname><given-names>Ekaterina V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>врач эндокринолог, клинический ординатор кафедры эндокринологии и диабетологии</p></bio><bio xml:lang="en"><p>endocrinologist, clinical resident of the Department of Endocrinology and Diabetology</p></bio><email xlink:type="simple">perinatal_nk@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4865-5826</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зорин</surname><given-names>Николай Алексеевич</given-names></name><name name-style="western" xml:lang="en"><surname>Zorin</surname><given-names>Nikolay A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доктор биологических наук, профессор, заведующий научно-исследовательской лаборатории иммунологии</p></bio><bio xml:lang="en"><p>Doctor of Biological Sciences, Professor, Head of the Scientific Laboratory of Immunology</p></bio><email xlink:type="simple">macroglobulin@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>&lt;p&gt;Новокузнецкий государственный институт усовершенствования врачей &amp;mdash; филиал ФГБОУ ДПО &amp;laquo;Российская медицинская академия непрерывного профессионального образования&amp;raquo; Минздрава России&lt;/p&gt;</institution><country>Россия</country></aff><aff xml:lang="en"><institution>&lt;p&gt;Novokuznetsk State Institute for Further Training of Physicians &amp;mdash; Branch Campus of the Russian Medical Academy of Continuous Professional Education&lt;/p&gt;</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>14</day><month>05</month><year>2019</year></pub-date><volume>65</volume><issue>1</issue><fpage>4</fpage><lpage>9</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Маклакова Т.П., Зорина В.Н., Янышева А.В., Мезенцева Е.В., Зорин Н.А., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Маклакова Т.П., Зорина В.Н., Янышева А.В., Мезенцева Е.В., Зорин Н.А.</copyright-holder><copyright-holder xml:lang="en">Maklakova T.P., Zorina V.N., Yanysheva A.V., Mezentseva E.V., Zorin N.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.probl-endojournals.ru/jour/article/view/9567">https://www.probl-endojournals.ru/jour/article/view/9567</self-uri><abstract><sec><title>Обоснование</title><p>Обоснование. Иммунорегуляторные белки (альфа-2-макроглобулин, лактоферрин) активно участвуют в воспалительных и аутоиммунных процессах, влияют на синтез и транспорт гормонов и цитокинов, контролируют пролиферацию и апоптоз клеток. Однако роль этих белков в патогенезе болезни Грейвса (БГ) практически не изучена.</p><p>Цель исследования — определить содержание альфа-2-макроглобулина (α2-МГ), лактоферрина (ЛФ) и цитокинов (ФНО-α, ИЛ-6, ИЛ-8 и ИФН-γ) в крови при БГ.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В крови 50 пациенток с БГ в стадиях декомпенсации и компенсации (через 4–6 мес и 1,5–2 года после начала лечения) и 25 здоровых женщин (контрольная группа) определяли содержание ТТГ, свободного Т4, антител к рецептору ТТГ, ФНО-α, ИЛ-6, ИЛ-8, ИФН-γ и ЛФ иммуноферментным методом и также α2-МГ методом количественного ракетного иммуноэлектрофореза.</p></sec><sec><title>Результаты</title><p>Результаты. БГ при манифестации клинически проявлялась снижением массы тела у 84% пациентов, синусовой тахикардией практически у всех обследованных, пароксизмальной мерцательной аритмией у 18%, эндокринной офтальмопатией у 12% и неврологическими сдвигами. В стадии декомпенсации БГ были статистически значимо повышены уровни ИФН-γ, ИЛ-6 и α2-МГ и особенно существенно — ИЛ-8 и ЛФ. Через 4–6 мес после начала лечения клинические проявления были купированы у всех больных, уровни ИЛ-6 и α2-МГ снизились, но концентрации антител к рецептору ТТГ (АТ-рТТГ), ИЛ-8, ИФН-γ и ЛФ оставались повышенными. Через 1,5— 2 года уровни изученных белков и цитокинов не отличались от таковых у лиц контрольной группы.</p></sec><sec><title>Выводы</title><p>Выводы. Повышение содержания в крови ИЛ-8, ЛФ, ИЛ-6 и α2-МГ при первично выявленной или рецидивирующей БГ и снижение их уровня при лечении подтверждают участие иммунорегуляторных белков в патогенезе заболевания.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. Immunoregulatory proteins (alpha-2-macroglobulin, lactoferrin) actively participate in inflammatory and autoimmune processes, affect synthesis and transport of hormones and cytokines, and control cell proliferation and apoptosis. However, the role of these proteins in the pathogenesis of Graves’ disease (GD) is poorly understood.</p><p>Objective — the study objective was to determine blood levels of alpha-2-macroglobulin (α2-MG), lactoferrin (LF), and cytokines (TNF-α, IL-6, IL-8, and IFN-γ) in GD.</p></sec><sec><title>Material and methods</title><p>Material and methods. We determined blood levels of TSH, free T4, TSH receptor antibodies, TNF-α, IL-6, IL-8, IFN-γ, and LF by ELISA as well as α2-MG by quantitative rocket immunoelectrophoresis in 50 patients with decompensated and compensated (4―6 months and 1.5―2 years after treatment onset) GD and 25 healthy females (control group).</p></sec><sec><title>Results</title><p>Results. GD clinically manifested by body weight l in 84% of patients, sinus tachycardia in almost all patients, paroxysmal atrial fibrillation in 18% of cases, endocrine ophthalmopathy in 12% of patients, and neurological changes. In decompensated GD, there was a statistically significant increase in levels of IFN-γ, IL-6, and α2-MG and an especially significant increase in levels of IL-8 and LF. At 4―6 months after treatment onset, clinical manifestations were stopped in all patients, levels of IL-6 and α2-MG decreased, but the concentrations of TSH receptor antibodies (TSHR-Abs), IL-8, IFN-γ, and LF remained elevated. At 1.5―2 years, levels of the studied proteins and cytokines did not differ from those in the control group.</p></sec><sec><title>Conclusion</title><p>Conclusion. An increase in blood levels of IL-8, LF, IL-6, and α2-MG in incident or recurrent GD and a decrease in the levels during treatment confirm involvement of immunoregulatory proteins in pathogenesis of the disease.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>болезнь Грейвса</kwd><kwd>альфа-2-макроглобулин</kwd><kwd>лактоферрин</kwd><kwd>цитокины</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Graves’ disease</kwd><kwd>alpha-2-macroglobulin</kwd><kwd>lactoferrin</kwd><kwd>cytokines</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Лазанович В.В., Маркелова Е.В. Показатели цитокинового статуса, тиреоидных аутоантител и их динамические изменения на фоне лечения болезни Грейвса. // Клиническая экспериментальная тиреоидология. — 2008. — Т. 4. — №3. — С. 28-35. [Lazanovich VV, Markelova EV. Cytokine status, thyroid autoantibodies and their dynamic changes during the treatment of graves’ disease. Clinical and Experimental Thyroidology. 2008; 4(3):28-35. (In Russ.)]. doi: https://doi.org/10.14341/ket20084328-35</mixed-citation><mixed-citation xml:lang="en">Лазанович В.В., Маркелова Е.В. Показатели цитокинового статуса, тиреоидных аутоантител и их динамические изменения на фоне лечения болезни Грейвса. // Клиническая экспериментальная тиреоидология. — 2008. — Т. 4. — №3. — С. 28-35. [Lazanovich VV, Markelova EV. Cytokine status, thyroid autoantibodies and their dynamic changes during the treatment of graves’ disease. Clinical and Experimental Thyroidology. 2008; 4(3):28-35. (In Russ.)]. doi: https://doi.org/10.14341/ket20084328-35</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Ganesh BB, Bhattacharya P, Gopisetty A, Prabhakar BS. Role of cytokines in the pathogenesis and suppression of thyroid autoimmunity. J Interferon Cytokine Res. 2011;31(10):721-731. doi: https://doi.org/10.1089/jir.2011.0049</mixed-citation><mixed-citation xml:lang="en">Ganesh BB, Bhattacharya P, Gopisetty A, Prabhakar BS. Role of cytokines in the pathogenesis and suppression of thyroid autoimmunity. J Interferon Cytokine Res. 2011;31(10):721-731. doi: https://doi.org/10.1089/jir.2011.0049</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Кандрор В.И. Механизмы развития болезни Грейвса и действия тиреоидных гормонов. // Клиническая и экспериментальная тиреоидология. — 2008. — Т. 4. — №1. — С. 26-34. [Kandror VI. Pathogenesis of graves disease and mechanism of action of thiroid hormones. Clinical and Experimental Thyroidology. 2008;4(1):26-34. (In Russ.)]. doi: https://doi.org/10.14341/ket20084126-34</mixed-citation><mixed-citation xml:lang="en">Кандрор В.И. Механизмы развития болезни Грейвса и действия тиреоидных гормонов. // Клиническая и экспериментальная тиреоидология. — 2008. — Т. 4. — №1. — С. 26-34. [Kandror VI. Pathogenesis of graves disease and mechanism of action of thiroid hormones. Clinical and Experimental Thyroidology. 2008;4(1):26-34. (In Russ.)]. doi: https://doi.org/10.14341/ket20084126-34</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Здор В.В., Маркелова Е.В. Уровень сывороточных цитокинов, трансформирующего фактора роста-Β, IL-17, IL-10, IL-1α и ILl-1β в дебюте аутоиммунного тиреотоксикоза при болезни Грейвса—Базедова. // Медицинская Иммунология. — 2011. — Т. 13. — №4-5. — С. 366. [Zdor VV, Markelova EV. Uroven’ syvorotochnykh tsitokinov, transformiruyushchego faktora rosta-Β, IL-17, IL-10, IL-1α and IL-1β v debyute autoimmunnogo tireotoksikoza pri bolezni Greyvsa—Bazedova. Meditsinskaya Immunologiya. 2011;13(4-5):366. (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Здор В.В., Маркелова Е.В. Уровень сывороточных цитокинов, трансформирующего фактора роста-Β, IL-17, IL-10, IL-1α и ILl-1β в дебюте аутоиммунного тиреотоксикоза при болезни Грейвса—Базедова. // Медицинская Иммунология. — 2011. — Т. 13. — №4-5. — С. 366. [Zdor VV, Markelova EV. Uroven’ syvorotochnykh tsitokinov, transformiruyushchego faktora rosta-Β, IL-17, IL-10, IL-1α and IL-1β v debyute autoimmunnogo tireotoksikoza pri bolezni Greyvsa—Bazedova. Meditsinskaya Immunologiya. 2011;13(4-5):366. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Eshaghkhani Y, Sanati MH, Nakhjavani M, et al. Disturbed Th1 and Th2 balance in patients with graves’ disease. Minerva Endocrinol. 2016;41(1):28-36.</mixed-citation><mixed-citation xml:lang="en">Eshaghkhani Y, Sanati MH, Nakhjavani M, et al. Disturbed Th1 and Th2 balance in patients with graves’ disease. Minerva Endocrinol. 2016;41(1):28-36.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Antonelli A, Ferrari SM, Corrado A, et al. Increase of interferon-gamma inducible CXCl9 and CXCl11 serum levels in patients with active graves’ disease and modulation by methimazole therapy. Thyroid. 2013;23(11):1461-1469. doi: https://doi.org/10.1089/thy.2012.0485</mixed-citation><mixed-citation xml:lang="en">Antonelli A, Ferrari SM, Corrado A, et al. Increase of interferon-gamma inducible CXCl9 and CXCl11 serum levels in patients with active graves’ disease and modulation by methimazole therapy. Thyroid. 2013;23(11):1461-1469. doi: https://doi.org/10.1089/thy.2012.0485</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Gu LQ, Jia HY, Zhao YJ, et al. Association studies of Interleukin-8 gene in graves’ disease and graves’ ophthalmopathy. Endocrine. 2009;36(3):452-456. doi: https://doi.org/10.1007/s12020-009-9240-9</mixed-citation><mixed-citation xml:lang="en">Gu LQ, Jia HY, Zhao YJ, et al. Association studies of Interleukin-8 gene in graves’ disease and graves’ ophthalmopathy. Endocrine. 2009;36(3):452-456. doi: https://doi.org/10.1007/s12020-009-9240-9</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Зорин Н.А., Зорина В.Н. Сигнальная система макроглобулинов. (Обзор литературы). // Биомедицинская химия. — 2012. — Т. 58. — №4. — С. 400-410. [Zorin NA, Zorina VN. Signal’naya sistema makroglobulinov. Obzor Literatury. Biomeditsinskaya khimiya. 2012;58(4):400-410. (In Russ.)]. doi: https://doi.org/10.18097/pbmc20125804400</mixed-citation><mixed-citation xml:lang="en">Зорин Н.А., Зорина В.Н. Сигнальная система макроглобулинов. (Обзор литературы). // Биомедицинская химия. — 2012. — Т. 58. — №4. — С. 400-410. [Zorin NA, Zorina VN. Signal’naya sistema makroglobulinov. Obzor Literatury. Biomeditsinskaya khimiya. 2012;58(4):400-410. (In Russ.)]. doi: https://doi.org/10.18097/pbmc20125804400</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Legrand D, Elass E, Carpentier M, Mazurier J. Lactoferrin: a modulator of immune and inflammatory responses. Cell Mol Life Sci. 2005;62(22):2549-2559. doi: https://doi.org/10.1007/s00018-005-5370-2</mixed-citation><mixed-citation xml:lang="en">Legrand D, Elass E, Carpentier M, Mazurier J. Lactoferrin: a modulator of immune and inflammatory responses. Cell Mol Life Sci. 2005;62(22):2549-2559. doi: https://doi.org/10.1007/s00018-005-5370-2</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Трошина Е.А., Свириденко Н.Ю., Ванушко В.Е., и др. Федеральные клинические рекомендации по диагностике и лечению токсического зоба. // Проблемы эндокринологии. — 2014. — Т. 60. — №6.— С. 67-77. [Troshina EA, Sviridenko NYu, Vanushko VE, et al. The Federal clinical recommendations on diagnostics and treatment of toxic goiter. Problems of Endocrinology. 2014;60(6):67-77. (In Russ.)]. doi: https://doi.org/10.14341/probl201460667-77</mixed-citation><mixed-citation xml:lang="en">Трошина Е.А., Свириденко Н.Ю., Ванушко В.Е., и др. Федеральные клинические рекомендации по диагностике и лечению токсического зоба. // Проблемы эндокринологии. — 2014. — Т. 60. — №6.— С. 67-77. [Troshina EA, Sviridenko NYu, Vanushko VE, et al. The Federal clinical recommendations on diagnostics and treatment of toxic goiter. Problems of Endocrinology. 2014;60(6):67-77. (In Russ.)]. doi: https://doi.org/10.14341/probl201460667-77</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ajjan RA, Weetman AP. Cytokines in thyroid autoimmunity. Autoimmunity. 2009;36(6-7):351-359. doi: https://doi.org/10.1080/08916930310001603046</mixed-citation><mixed-citation xml:lang="en">Ajjan RA, Weetman AP. Cytokines in thyroid autoimmunity. Autoimmunity. 2009;36(6-7):351-359. doi: https://doi.org/10.1080/08916930310001603046</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Weetman AP. Cellular immune responses in autoimmune thyroid isease. Clin Endocrinol (Oxf). 2004;61(4):405-413. doi: https://doi.org/10.1111/j.1365-2265.2004.02085.x</mixed-citation><mixed-citation xml:lang="en">Weetman AP. Cellular immune responses in autoimmune thyroid isease. Clin Endocrinol (Oxf). 2004;61(4):405-413. doi: https://doi.org/10.1111/j.1365-2265.2004.02085.x</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Gianoukakis AG, Khadavi N, Smith TJ. Cytokines, graves’ disease, and thyroid-associated ophthalmopathy. Thyroid. 2008;18(9):953-958. doi: https://doi.org/10.1089/thy.2007.0405</mixed-citation><mixed-citation xml:lang="en">Gianoukakis AG, Khadavi N, Smith TJ. Cytokines, graves’ disease, and thyroid-associated ophthalmopathy. Thyroid. 2008;18(9):953-958. doi: https://doi.org/10.1089/thy.2007.0405</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Саприна Т.В., Прохоренко Т.С., Новицкий В.В. Аутоиммунные тиреопатии. Молекулярные подходы к дифференциальной диагностике. — Томск: Издательство СибГМУ; 2017. [Saprina TV, Prokhorenko TS, Novitskiy VV. Autoimmunnye tireopatii. Molekulyarnye podkhody k differentsial’noy diagnostike. Tomsk: Izdatel’stvo SibGMU; 2017. (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Саприна Т.В., Прохоренко Т.С., Новицкий В.В. Аутоиммунные тиреопатии. Молекулярные подходы к дифференциальной диагностике. — Томск: Издательство СибГМУ; 2017. [Saprina TV, Prokhorenko TS, Novitskiy VV. Autoimmunnye tireopatii. Molekulyarnye podkhody k differentsial’noy diagnostike. Tomsk: Izdatel’stvo SibGMU; 2017. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Шарипова З.Ф., Фархутдинова Л.M. Взаимосвязь иммунологического статуса и микроэлементного профиля организма при тиреопатиях. // Врач. — 2007. — №S. — С. 51-52. [Sharipova ZF, Farkhutdinova LM. Vzaimosvyaz’ immunologicheskogo statusa I mikroelementnogo profilya organizma pri tireopatiyakh. Vrach. 2007;(S):51-52. (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Шарипова З.Ф., Фархутдинова Л.M. Взаимосвязь иммунологического статуса и микроэлементного профиля организма при тиреопатиях. // Врач. — 2007. — №S. — С. 51-52. [Sharipova ZF, Farkhutdinova LM. Vzaimosvyaz’ immunologicheskogo statusa I mikroelementnogo profilya organizma pri tireopatiyakh. Vrach. 2007;(S):51-52. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Wu SM, Patel DD, Pizzo SV. Oxidized alpha2-Macroglobulin (Alpha2m) differentially regulates receptor binding by cytokines/growth factors: implications for tissue injury and repair mechanisms in inflammation. J Immunol. 1998;161(8):4356-4365.</mixed-citation><mixed-citation xml:lang="en">Wu SM, Patel DD, Pizzo SV. Oxidized alpha2-Macroglobulin (Alpha2m) differentially regulates receptor binding by cytokines/growth factors: implications for tissue injury and repair mechanisms in inflammation. J Immunol. 1998;161(8):4356-4365.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Lamarre J, Wolf BB, Kittler EL, et al. Regulation of macrophage alpha2-macroglobulin receptor/low density lipoprotein receptor-related protein by lipopolysaccharide and interferon-gamma. J Clin Invest. 1993;91(3):1219-1224. doi: https://doi.org/10.1172/jci116283</mixed-citation><mixed-citation xml:lang="en">Lamarre J, Wolf BB, Kittler EL, et al. Regulation of macrophage alpha2-macroglobulin receptor/low density lipoprotein receptor-related protein by lipopolysaccharide and interferon-gamma. J Clin Invest. 1993;91(3):1219-1224. doi: https://doi.org/10.1172/jci116283</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
